Ozempic has become one of the most searched health topics in India. Whether you live with diabetes or are exploring medically supervised weight management, the underlying questions are similar — what is it, how does it work, is it right for me, and how do I use it safely? This guide answers those questions in plain language.

As a practising diabetologist in Greater Noida with over 15 years of experience, here is my honest, educational overview of semaglutide (Ozempic) in India in 2026. This page is for information only — it is not medical advice, an advertisement, or a recommendation of any product, and it does not provide drug prices.

What Is Ozempic and How Does It Work?

Ozempic is a brand name for semaglutide, a once-weekly injectable medicine made by Novo Nordisk. It belongs to a class called GLP-1 receptor agonists — medicines that mimic a gut hormone to help regulate blood sugar, reduce appetite, and slow gastric emptying.

In simple terms, semaglutide helps the body release insulin when blood sugar is high, reduces the amount of sugar the liver produces, and increases the feeling of fullness — which can improve blood sugar control and support weight reduction.

What Changed in 2026

The Indian patent for semaglutide expired on 20 March 2026. Within weeks, several DCGI-approved Indian manufacturers launched their own versions, and the originator also revised its India pricing. The overall effect is that this class of medicine is now considerably more affordable and accessible than it was previously.

That is genuinely positive for public health — but accessibility is not the same as suitability. A medicine being cheaper does not make it right for everyone, and the decision to start should always follow a proper assessment. For most people, the appropriate first step is a clinical evaluation, not a purchase.

What About the Cost?

Price is the most common question patients ask. Since the patent expired, the cost of semaglutide in India has fallen substantially, and it varies widely by brand, formulation (vial versus pen), dose, city and pharmacy — and continues to change as more products launch.

Because cost should never be the main basis for a medical decision, I do not publish specific drug prices on this page. For accurate, current pricing, ask your treating physician or a licensed pharmacy. In consultation, the more important questions are whether this class of medicine is appropriate for you at all, which formulation suits you, and how to use it safely.

Brands You May Hear About

It helps to separate the molecule from the brand name. Semaglutide is known by the originator brand names Ozempic (type-2 diabetes), Wegovy (chronic weight management) and Rybelsus (the oral tablet). Since the 2026 patent expiry, the same molecule is also produced by several DCGI-approved Indian manufacturers under a range of brand names. A separate, newer molecule, tirzepatide, is marketed as Mounjaro and does not yet have an Indian generic.

Semaglutide and Tirzepatide — How They Differ

The two molecules in this category differ in how they are taken and how they act. The descriptions below are general education; effects vary between individuals.

There is no single "best" medicine — the right choice depends entirely on the individual, and is made with a physician. You can read more about supervised care on our medical weight-loss programme page.

Who Might Be a Candidate? — Medical Eligibility

Semaglutide is not a casual weight-loss product. It is a prescription medicine that requires proper evaluation. A physician may consider it for people with:

• Type-2 diabetes not adequately controlled with metformin or other oral medicines
• BMI over 30 (clinical obesity), with or without diabetes
• BMI over 27 with conditions such as hypertension, sleep apnoea, or insulin resistance
• PCOS-related metabolic weight gain not responding to lifestyle changes alone
• Persistent insulin resistance despite a structured diet and exercise plan

Common Side Effects — What to Expect

Most side effects occur during the first 2–4 weeks as the body adjusts:

• Nausea — the most common effect, usually mild and temporary
• Vomiting and diarrhoea — typically settle within the first few weeks
• Constipation — often managed with diet and hydration
• Abdominal discomfort — smaller, lighter meals can help
• Reduced appetite — part of the therapeutic effect, but extreme loss of appetite should be reported

Serious but rare risks include pancreatitis and gallbladder problems. This is precisely why these medicines should be used only under the supervision of a trained physician who monitors kidney function, pancreatic health, and nutritional status throughout treatment. At our clinic, supervised care includes regular blood work and follow-up.

The Danger of Self-Medicating With "Weight-Loss Pens"

With rising interest in GLP-1 medicines, more people are buying semaglutide pens online without a prescription. This is dangerous for several reasons:

• Incorrect dosing can cause severe nausea, dehydration, and electrolyte imbalance
• Without baseline blood tests, underlying conditions (thyroid, pancreatic, kidney) may be missed
• Unmonitored use can lead to muscle loss instead of fat loss
• Counterfeit products are a real risk in a crowded market — obtain medicines only from licensed pharmacies
• Starting at the wrong dose is a frequent cause of intolerable side effects and stopping treatment altogether

I have seen patients who began self-medicating and developed complications that proper oversight could have prevented. The cost of a consultation is a fraction of the cost of managing such complications. This is the core message of my companion post on common GLP-1 mistakes a diabetologist sees every week.

A "Metabolic First" Approach to Care

At Nirvana Clinic, Greater Noida, supervised GLP-1 care follows a structured approach:

• Comprehensive metabolic workup before any prescription — HbA1c, fasting insulin, lipid profile, kidney and liver function, thyroid panel
• Clinical suitability first — deciding whether a GLP-1 medicine is appropriate at all, rather than assuming it is
• Personalised dose escalation — starting low and increasing only as needed, to minimise side effects
• Nutritional monitoring — protecting muscle, not just lowering the number on the scale
• Regular follow-ups — blood work at 4, 8, and 12 weeks to track progress safely
• Medicine plus lifestyle — integrating treatment with diet and activity, not replacing them

Read more about our diabetes care programme and diabetes reversal approach.

Frequently Asked Questions